Literature DB >> 24700732

Analysis of TP53 mutation status in human cancer cell lines: a reassessment.

Bernard Leroy1, Luc Girard, Antoinette Hollestelle, John D Minna, Adi F Gazdar, Thierry Soussi.   

Abstract

Tumor-derived cell lines play an important role in the investigation of tumor biology and genetics. Across a wide array of studies, they have been tools of choice for the discovery of important genes involved in cancer and for the analysis of the cellular pathways that are impaired by diverse oncogenic events. They are also invaluable for screening novel anticancer drugs. The TP53 protein is a major component of multiple pathways that regulate cellular response to various types of stress. Therefore, TP53 status affects the phenotype of tumor cell lines profoundly and must be carefully ascertained for any experimental project. In the present review, we use the 2014 release of the UMD TP53 database to show that TP53 status is still controversial for numerous cell lines, including some widely used lines from the NCI-60 panel. Our analysis clearly confirms that, despite numerous warnings, the misidentification of cell lines is still present as a silent and neglected issue, and that extreme care must be taken when determining the status of p53, because errors may lead to disastrous experimental interpretations. A novel compendium gathering the TP53 status of 2,500 cell lines has been made available (http://p53.fr). A stand-alone application can be used to browse the database and extract pertinent information on cell lines and associated TP53 mutations. It will be updated regularly to minimize any scientific issues associated with the use of misidentified cell lines (http://p53.fr).
© 2014 WILEY PERIODICALS, INC.

Entities:  

Keywords:  TP53; cancer cell line; cross-contamination; misidentification; recommendation

Mesh:

Substances:

Year:  2014        PMID: 24700732      PMCID: PMC4451114          DOI: 10.1002/humu.22556

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  46 in total

1.  Persistent use of misidentified cell lines and its prevention.

Authors:  Roderick A F MacLeod; Willy G Dirks; Hans G Drexler
Journal:  Genes Chromosomes Cancer       Date:  2002-01       Impact factor: 5.006

2.  p53 alterations in human leukemia-lymphoma cell lines: in vitroartifact or prerequisite for cell immortalization?

Authors:  H G Drexler; S Fombonne; Y Matsuo; Z B Hu; H Hamaguchi; C C Uphoff
Journal:  Leukemia       Date:  2000-01       Impact factor: 11.528

Review 3.  Cross-contamination of cells in culture.

Authors:  W A Nelson-Rees; D W Daniels; R R Flandermeyer
Journal:  Science       Date:  1981-04-24       Impact factor: 47.728

4.  p53 mutations in colorectal cancer.

Authors:  N R Rodrigues; A Rowan; M E Smith; I B Kerr; W F Bodmer; J V Gannon; D P Lane
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

5.  Clonality and stability of the p53 gene in human astrocytic tumor cells: quantitative analysis of p53 gene mutations by yeast functional assay.

Authors:  M Tada; R D Iggo; N Ishii; Y Shinohe; S Sakuma; A Estreicher; Y Sawamura; H Abe
Journal:  Int J Cancer       Date:  1996-07-29       Impact factor: 7.396

6.  Alternative splicing of the p53 tumor suppressor gene in the Molt-4 T-lymphoblastic leukemia cell line.

Authors:  V T Chow; H H Quek; E P Tock
Journal:  Cancer Lett       Date:  1993-09-30       Impact factor: 8.679

7.  Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles.

Authors:  W B Isaacs; B S Carter; C M Ewing
Journal:  Cancer Res       Date:  1991-09-01       Impact factor: 12.701

Review 8.  Recommendations for analyzing and reporting TP53 gene variants in the high-throughput sequencing era.

Authors:  Thierry Soussi; Bernard Leroy; Peter E M Taschner
Journal:  Hum Mutat       Date:  2014-05-06       Impact factor: 4.878

9.  Global proteome analysis of the NCI-60 cell line panel.

Authors:  Amin Moghaddas Gholami; Hannes Hahne; Zhixiang Wu; Florian Johann Auer; Chen Meng; Mathias Wilhelm; Bernhard Kuster
Journal:  Cell Rep       Date:  2013-08-08       Impact factor: 9.423

10.  K-ras and p53 alterations in genomic DNA and transcripts of human pancreatic adenocarcinoma cell lines.

Authors:  H Suwa; T Yoshimura; N Yamaguchi; K Kanehira; T Manabe; M Imamura; H Hiai; M Fukumoto
Journal:  Jpn J Cancer Res       Date:  1994-10
View more
  79 in total

1.  Identification of pharmacodynamic biomarkers and common molecular mechanisms of response to genotoxic agents in cancer cell lines.

Authors:  Dong-Joon Min; Yingdong Zhao; Anne Monks; Alida Palmisano; Curtis Hose; Beverly A Teicher; James H Doroshow; Richard M Simon
Journal:  Cancer Chemother Pharmacol       Date:  2019-07-31       Impact factor: 3.333

2.  Cancer Cells Employ Nuclear Caspase-8 to Overcome the p53-Dependent G2/M Checkpoint through Cleavage of USP28.

Authors:  Ines Müller; Elwira Strozyk; Sebastian Schindler; Stefan Beissert; Htoo Zarni Oo; Thomas Sauter; Philippe Lucarelli; Sebastian Raeth; Angelika Hausser; Nader Al Nakouzi; Ladan Fazli; Martin E Gleave; He Liu; Hans-Uwe Simon; Henning Walczak; Douglas R Green; Jiri Bartek; Mads Daugaard; Dagmar Kulms
Journal:  Mol Cell       Date:  2020-01-22       Impact factor: 17.970

3.  Humanin Blocks the Aggregation of Amyloid-β Induced by Acetylcholinesterase, an Effect Abolished in the Presence of IGFBP-3.

Authors:  Deanna Price; Sadaf Dorandish; Asana Williams; Brandon Iwaniec; Alexis Stephens; Keyan Marshall; Jeffrey Guthrie; Deborah Heyl; Hedeel Guy Evans
Journal:  Biochemistry       Date:  2020-05-20       Impact factor: 3.162

4.  Exposure of the extracellular matrix and colonization of the ovary in metastasis of fallopian-tube-derived cancer.

Authors:  Matthew Dean; Vivian Jin; Angela Russo; Daniel D Lantvit; Joanna E Burdette
Journal:  Carcinogenesis       Date:  2019-03-12       Impact factor: 4.944

5.  A systematic analysis reveals heterogeneous changes in the endocytic activities of cancer cells.

Authors:  Sarah R Elkin; Nawal Bendris; Carlos R Reis; Yunyun Zhou; Yang Xie; Kenneth E Huffman; John D Minna; Sandra L Schmid
Journal:  Cancer Res       Date:  2015-09-10       Impact factor: 12.701

Review 6.  Autophagy in malignant transformation and cancer progression.

Authors:  Lorenzo Galluzzi; Federico Pietrocola; José Manuel Bravo-San Pedro; Ravi K Amaravadi; Eric H Baehrecke; Francesco Cecconi; Patrice Codogno; Jayanta Debnath; David A Gewirtz; Vassiliki Karantza; Alec Kimmelman; Sharad Kumar; Beth Levine; Maria Chiara Maiuri; Seamus J Martin; Josef Penninger; Mauro Piacentini; David C Rubinsztein; Hans-Uwe Simon; Anne Simonsen; Andrew M Thorburn; Guillermo Velasco; Kevin M Ryan; Guido Kroemer
Journal:  EMBO J       Date:  2015-02-23       Impact factor: 11.598

7.  The potential roles of lncRNAs DUXAP8, LINC00963, and FOXD2-AS1 in luminal breast cancer based on expression analysis and bioinformatic approaches.

Authors:  Maedeh Arabpour; Sepideh Mehrpour Layeghi; Javad Tavakkoly Bazzaz; Mohammad Mehdi Naghizadeh; Keivan Majidzadeh-A; Abbas Shakoori
Journal:  Hum Cell       Date:  2021-05-27       Impact factor: 4.174

8.  Combined p53- and PTEN-deficiency activates expression of mesenchyme homeobox 1 (MEOX1) required for growth of triple-negative breast cancer.

Authors:  Mari Gasparyan; Miao-Chia Lo; Hui Jiang; Chang-Ching Lin; Duxin Sun
Journal:  J Biol Chem       Date:  2020-05-28       Impact factor: 5.157

Review 9.  Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease?

Authors:  Danielly C F Costa; Guilherme A P de Oliveira; Elio A Cino; Iaci N Soares; Luciana P Rangel; Jerson L Silva
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-10-03       Impact factor: 10.005

10.  The deubiquitinase USP7 stabilizes Maf proteins to promote myeloma cell survival.

Authors:  Yuanming He; Siyu Wang; Jiefei Tong; Shuoyi Jiang; Ye Yang; Zubin Zhang; Yujia Xu; Yuanying Zeng; Biyin Cao; Michael F Moran; Xinliang Mao
Journal:  J Biol Chem       Date:  2019-12-10       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.